CC BY-NC-ND 4.0 · Horm Metab Res 2024; 56(01): 99-106 DOI: 10.1055/a-2172-7228
Review
Salt and Aldosterone – Reciprocal and Combined Effects in
Preclinical Models and Humans
Li Chen
1
Medizinische Klinik und Poliklinik IV, LMU Klinikum, LMU
München, München, Germany
,
Christian Adolf
1
Medizinische Klinik und Poliklinik IV, LMU Klinikum, LMU
München, München, Germany
,
Martin Reincke
1
Medizinische Klinik und Poliklinik IV, LMU Klinikum, LMU
München, München, Germany
,
Holger Schneider
1
Medizinische Klinik und Poliklinik IV, LMU Klinikum, LMU
München, München, Germany
› Author AffiliationsFunding Information
This work was supported by the Else Kröner-Fresenius Stiftung in support of
the German Conn’s Registry-Else-Kröner Hyperaldosteronism Registry
(2013_A182, 2015_A171 and 2019_A104 to MR), the European Research Council (ERC)
under the European Union’s Horizon 2020 research and innovation program
(grant agreement No. 694913 to MR), by the Deutsche Forschungsgemeinschaft (DFG)
within the CRC/Transregio 205/2, (project No. 314061271)
“The Adrenal: Central Relay in Health and Disease” to CA, HS, and MR
and within the Clinician Scientist Program In Vascular MEdicine (PRIME) MA
2186/14-1 to HS, by the Förderprogramm für Forschung und
Lehre (FöFoLe) Reg.-Nr 1051 to CA and by grants from the China Scholarship
Council(CSC) — 202106940008 to LC.
Primary aldosteronism is an endocrine disorder caused by excessive production of
aldosterone by the adrenal glands, and is recognized as the most important cause
of endocrine hypertension. With specific therapy, this type of hypertension is
potentially curable. In the general population, high salt intake increases the
risk for cardiovascular diseases like stroke. In populations with aldosterone
excess, observational and experimental data suggest that aldosterone-induced
organ damage requires a combination of high dietary salt intake and high plasma
aldosterone, i.e., plasma aldosterone levels inappropriately high for salt
status. Therefore, understanding the relationship between plasma aldosterone
levels and dietary salt intake and the nature of their combined effects is
crucial for developing effective prevention and treatment strategies. In this
review, we present an update on findings about primary aldosteronism and salt
intake and the underlying mechanisms governing their interaction.
Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
References
1
Rossier BC,
Baker ME,
Studer RA.
Epithelial sodium transport and its control by aldosterone: The story of our
internal environment revisited. Physiol Rev 2015; 95: 297-340
6
Vohra T,
Kemter E,
Sun N.
et al.
Effect of dietary sodium modulation on pig adrenal steroidogenesis and
transcriptome profiles. Hypertension 2020; 1769-1777
7
Williams TA,
Monticone S,
Crudo V.
et al.
Visinin-like 1 is upregulated in aldosterone-producing adenomas with KCNJ5
mutations and protects from calcium-induced apoptosis. Hypertension 2012; 59: 833-839
9
McGraw AP,
Bagley J,
Chen WS.
et al.
Aldosterone increases early atherosclerosis and promotes plaque inflammation
through a placental growth factor-dependent mechanism. J Am Heart Assoc 2013; 2: 1-14
11
Kurtz TW,
Morris RC,
Pravenec M.
et al.
Hypertension in primary aldosteronism is initiated by salt-induced increases in
vascular resistance with reductions in cardiac output. Hypertension 2023; 80: 1077-1091
15
Whelton PK,
Carey RM,
Aronow WS.
et al.
2017
ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA
guideline for the prevention, detection, evaluation, and management of high
blood pressure in adults: a report of the American college of
cardiology/American heart association task force on clinical Pr. Hypertension 2018; 71: 13-115
16
Amine EK,
Baba NH,
Belhadj M.
et al
Diet, nutrition and the prevention of chronic diseases. World Health Organ Tech Rep Ser 2003; 916 i–viii 1-149 backcover
17
Ohno Y,
Sone M,
Inagaki N.
et al.
Prevalence of cardiovascular disease and its risk factors in primary
aldosteronism: a multicenter study in Japan. Hypertension 2018; 71: 530-537
18
Adolf C,
Görge V,
Heinrich DA.
et al.
Altered taste perception for sodium chloride in patients with primary
aldosteronism: a prospective cohort study. Hypertension 2021; 1332-1340
19
Adolf C,
Schneider H,
Heinrich DA.
et al.
Salt appetite and its effects on cardiovascular risk in primary
aldosteronism. Horm Metab Res 2020; 52: 386-393
20
Resch JM,
Fenselau H,
Madara JC.
et al.
Aldosterone-sensing neurons in the NTS exhibit state-dependent pacemaker
activity and drive sodium appetite via synergy with angiotensin II
signaling. Neuron 2017; 96: 190-206.e7
22
Oliver WJ,
Cohen EI,
Neel JV.
Blood pressure, sodium intake, and sodium related hormones in the Yanomamo
indians, a „no salt“ culture. Circulation 1975; 52: 146-151
25
Rocha R,
Rudolph AE,
Frierdich GE.
et al.
Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol 2002; 283: 1802-1810
26
Schewe J,
Seidel E,
Forslund S.
et al.
Elevated aldosterone and blood pressure in a mouse model of familial
hyperaldosteronism with ClC-2 mutation. Nat Commun 2019; 10: 5155
27
Göppner C,
Orozco IJ,
Hoegg-Beiler MB.
et al.
Pathogenesis of hypertension in a mouse model for human CLCN2 related
hyperaldosteronism. Nat Commun 2019; 10: 1-13
28
Makhanova N,
Hagaman J,
Kim HS.
et al.
Salt-sensitive blood pressure in mice with increased expression of aldosterone
synthase. Hypertension 2008; 51: 134-140
30
Uzu T,
Nishimura M,
Fujii T.
et al.
Changes in the circadian rhythm of blood pressure in primary aldosteronism in
response to dietary sodium restriction and adrenalectomy. J Hypertens 1998; 16: 1745-1748
31
Schneider H,
Sarkis A,
Sturm L.
et al.
Moderate dietary salt restriction improves blood pressure and mental
well‐being in patients with primary aldosteronism: The salt CONNtrol
trial. J Intern Med 2023; 294: 47-57
32
Stowasser M,
Sharman J,
Leano R.
et al.
Evidence for abnormal left ventricular structure and function in normotensive
individuals with familial hyperaldosteronism type I. J Clin Endocrinol Metab 2005; 90: 5070-5076
33
Young M,
Head G,
Funder J.
Determinants of cardiac fibrosis in experimental hypermineralocorticoid
states. Am J Physiol Endocrinol Metab 1995; 269: 657-662
35
Young M,
Funder J.
Mineralocorticoid action and sodium-hydrogen exchange: Studies in experimental
cardiac fibrosis. Endocrinology 2003; 144: 3848-3851
39
Chan C-K,
Yang W-S,
Lin Y-H.
et al.
Arterial stiffness is associated with clinical outcome and cardiorenal injury in
lateralized primary aldosteronism. J Clin Endocrinol Metab 2020; 105: e3950-e3960
40
Rocha R,
Martin-Berger CL,
Yang P.
et al.
Selective aldosterone blockade prevents angiotensin II/salt-induced
vascular inflammation in the rat heart. Endocrinology 2002; 143: 4828-4836
41
Pu Q,
Neves MF,
Virdis A.
et al.
Endothelin antagonism on aldosterone-induced oxidative stress and vascular
remodeling. Hypertension 2003; 42: 49-55
42
Leopold JA,
Dam A,
Maron BA.
et al.
Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate
dehydrogenase activity. Nat Med 2007; 13: 189-197
43
Oberleithner H,
Riethmüller C,
Schillers H.
et al.
Plasma sodium stiffens vascular endothelium and reduces nitric oxide
release. Proc Natl Acad Sci U S A 2007; 104: 16281-16286
44
Nishizaka MK,
Zaman MA,
Green SA.
et al.
Impaired endothelium-dependent flow-mediated vasodilation in hypertensive
subjects with hyperaldosteronism. Circulation 2004; 109: 2857-2861
45
Kishimoto S,
Oki K,
Maruhashi T.
et al.
Eplerenone improves endothelial function and arterial stiffness and inhibits
Rho-associated kinase activity in patients with idiopathic
hyperaldosteronism. J Hypertens 2019; 37: 1083-1095
46
Kishimoto S,
Oki K,
Maruhashi T.
et al.
A comparison of adrenalectomy and eplerenone on vascular function in patients
with aldosterone-producing adenoma. J Clin Endocrinol Metab 2020; 105: 2341-2386
47
Matsumoto T,
Oki K,
Kajikawa M.
et al.
Effect of aldosterone-producing adenoma on endothelial function and
rho-associated kinase activity in patients with primary aldosteronism. Hypertension 2015; 65: 841-848
50
Nishiyama A,
Yao L,
Nagai Y.
et al.
Possible contributions of reactive oxygen species and mitogen-activated protein
kinase to renal injury in aldosterone/salt-induced hypertensive
rats. Hypertension 2004; 43: 841-848
54
Bayorh MA,
Ganafa AA,
Emmett N.
et al.
Alterations in aldosterone and angiotensin II levels in salt-induced
hypertension. Clin Exp Hypertens 2005; 27: 355-367
55
Takeda Y,
Miyamori I,
Yoneda T.
et al.
Regulation of aldosterone synthase in human vascular endothelial cells by
angiotensin II and adrenocorticotropin. J Clin Endocrinol Metab 1996; 81: 2797-2800
57
Alesutan I,
Voelkl J,
Feger M.
et al.
Involvement of vascular aldosterone synthase in phosphate-induced osteogenic
transformation of vascular smooth muscle cells. Sci Rep 2017; 7: 1-15
58
Manunta P,
Hamilton BP,
Hamlyn JM.
Salt intake and depletion increase circulating levels of endogenous ouabain in
normal men. Am J Physiol Regul Integr Comp Physiol 2006; 290: 553-559
60
Dmitrieva RI,
Bagrov AY,
Lalli E.
et al.
Mammalian bufadienolide is synthesized from cholesterol in the adrenal cortex by
a pathway that is independent of cholesterol side-chain cleavage. Hypertension 2000; 36: 442-448
62
Tentori S,
Messaggio E,
Brioni E.
et al.
Endogenous ouabain and aldosterone are coelevated in the circulation of patients
with essential hypertension. J Hypertens 2016; 34: 2074-2080
63
Tomaschitz A,
Piecha G,
Ritz E.
et al.
Marinobufagenin in essential hypertension and primary aldosteronism: A
cardiotonic steroid with clinical and diagnostic implications. Clin Exp Hypertens 2015; 37: 108-115
64
Bagrov AY,
Roukoyatkina NI,
Pinaev AG.
et al.
Effects of two endogenous Na+,K+-ATPase inhibitors,
marinobufagenin and ouabain, on isolated rat aorta. Eur J Pharmacol 1995; 274: 151-158
66
Nagase M,
Matsui H,
Shibata S.
et al.
Salt-induced nephropathy in obese spontaneously hypertensive rats via
paradoxical activation of the mineralocorticoid receptor: Role of oxidative
stress. Hypertension 2007; 50: 877-883
67
Nagase M,
Ayuzawa N,
Kawarazaki W.
et al.
Oxidative stress causes mineralocorticoid receptor activation in rat
cardiomyocytes: role of small GTPase Rac1. Hypertension 2012; 59: 500-506
69
Fan CY,
Kawai Y,
Inaba S.
et al.
Synergy of aldosterone and high salt induces vascular smooth muscle hypertrophy
through up-regulation of NOX1. J Steroid Biochem Mol Biol 2008; 111: 29-36
71
Bier A,
Braun T,
Khasbab R.
et al.
A high salt diet modulates the gut microbiota and short chain fatty acids
production in a salt-sensitive hypertension rat model. Nutrients 2018; 10: 1-10
73
Liu Y,
Jiang Q,
Liu Z.
et al.
Alteration of gut microbiota relates to metabolic disorders in primary
aldosteronism patients. Front Endocrinol (Lausanne) 2021; 12: 1-11
74
Heijden Van Der CDCC,
Smeets EMM,
Aarntzen EHJG.
et al.
Arterial wall inflammation and increased hematopoietic activity in patients with
primary aldosteronism. J Clin Endocrinol Metab 2020; 105: 1-14
77
Huang L,
Trieu K,
Yoshimura S.
et al.
Effect of dose and duration of reduction in dietary sodium on blood pressure
levels: systematic review and meta-analysis of randomised trials. BMJ 2020; 368: 8-10
78
He FJ,
Ma Y,
Campbell NRC.
et al.
Formulas to estimate dietary sodium intake from spot urine alter
sodium-mortality relationship. Hypertension 2019; 74: 572-580
80
Yoshida Y,
Fujiki R,
Kinoshita M.
et al.
Importance of dietary salt restriction for patients with primary aldosteronism
during treatment with mineralocorticoid receptor antagonists: the potential
importance of post-treatment plasma renin levels. Hypertens Res 2023; 46: 100-107
81
Catena C,
Colussi GL,
Novello M.
et al.
Dietary salt intake is a determinant of cardiac changes after Ttreatment of
primary aldosteronism: a prospective study. Hypertension 2016; 68: 204-212
